Home   Logon   Mobile Site   Research and Commentary   About Us   Call 1.800.621.1675 or Email Us       Follow Us: 

Search by Ticker, Keyword or CUSIP       
Blog Home
Bob Carey
Chief Market Strategist
Click for Bio

Follow Bob on Twitter Follow Bob on LinkedIn View Videos on YouTube

  A Snapshot Of FDA Drug Approvals
Supporting Image for Blog Post

View from the Observation Deck  
  1. While the 42 new drugs approved by the Food and Drug Administration (FDA) so far this year reflects a slower pace than last year's record-setting 59 drugs, it is still a good year by recent standards.
  2. The 42 drugs approved to date tops the 35.6 average posted over the previous decade (2009-2018).  
  3. The director of the FDA's Center for Drug Evaluation and Research, Janet Woodcock, M.D., stated this past July that the elevated numbers of new approvals would be maintained or even increase, according to FiercePharma. Dr. Woodcock believes that the drug industry is just beginning to see the fruits of the human genome sequencing.
  4. In the first half of 2019, pharmaceutical companies raised the list price of branded drugs by an average of 5%, according to BioSpace.
  5. Tufts Center for the Study of Drug Development estimates that drug companies, on average, endure out-of-pocket costs approaching $1.4 billion for newly developed, FDA-approved prescription medicines, according to Policy & Medicine. 
  6. The Office of the Actuary at CMS estimates that U.S. health care spending grew at a rate of 4.6% to $3.6 trillion in 2018, or $11,172 per person, up from 2017's 4.2% rise, according to The Center for Biosimilars. Total prescription drug spending increased by 2.5% to $335 billion in 2018. 
This chart is for illustrative purposes only and not indicative of any actual investment. 

Download a PDF of this post, please click here.
Posted on Tuesday, December 17, 2019 @ 12:52 PM • Post Link Share: 
Print this post Printer Friendly

These posts were prepared by First Trust Advisors L.P., and reflect the current opinion of the authors. They are based upon sources and data believed to be accurate and reliable. Opinions and forward looking statements expressed are subject to change without notice. This information does not constitute a solicitation or an offer to buy or sell any security.
Search Posts

US Stock Markets Ended Dec. 13, 2019
US Economy and Credit Markets Ended Dec. 13, 2019
S&P 500 Index Earnings & Revenue Growth Rate Projections (2020 & 2021)
U.S. Stocks Have Outperformed Foreign Stocks Since President Trump Was Elected
US Stock Markets Ended Dec. 6, 2019
US Economy and Credit Markets Ended Dec. 6, 201
Checking in on the 10-Largest Stocks in the S&P 500 Index
Top-Performing S&P 500 Index Subsectors in 2019
US Stock Markets Ended Nov. 29, 2019
US Economy and Credit Markets Ended Nov. 29, 2019
Skip Navigation Links.
Search by Topic
Skip Navigation Links.

The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
First Trust Portfolios L.P.  Member SIPC and FINRA. (Form CRS)   •  First Trust Advisors L.P. (Form CRS)
Home |  Important Legal Information |  Privacy Policy |  California Privacy Policy |  Business Continuity Plan |  FINRA BrokerCheck
Copyright © 2022 All rights reserved.